As the worldwide burden of endometrial cancer continues to rise, interest is growing in the evaluation of early detection and prevention strategies among women at increased risk. Focusing efforts on women with postmenopausal bleeding (PMB), a common symptom of endometrial cancer, may be a useful strategy; however, PMB is not specific for endometrial cancer and is often caused by benign conditions. OBJECTIVE To provide a reference of the prevalence of PMB in endometrial cancers and the risk of endometrial cancer in women with PMB.
E ndometrial cancer is the most common gynecologic cancer in developed countries and accounts for nearly 5% of cancer cases and more than 2% of deaths due to cancer in women worldwide.
1 In regions such as North America and parts of Europe, the incidence of endometrial cancer is disproportionately higher than in other developed countries, which may be attributed to higher rates of obesity, as well as other important risk factors such as aging, early menarche, late menopause, nulliparity, and postmenopausal estrogen therapy use. 2 Unlike most cancers, the incidence of endometrial cancer and associated mortality rates have increased in recent years [3] [4] [5] [6] [7] and are projected to rise during the next 10 years. [8] [9] [10] [11] Most endometrial cancers are diagnosed at a localized stage and are often curable with surgery, with a 5-year survival of approximately 95%. In contrast, 5-year survival for late-stage (stage IV) endometrial cancer ranges from 16% to 45%. [12] [13] [14] However, studies evaluating early detection strategies for endometrial cancer are lacking, and at present no recommendation for population-based screening exists. In the era of precision prevention, emphasis on identifying individuals at high risk to maximize the positive outcomes of clinical interventions while avoiding unnecessary harms is growing. [15] [16] [17] Rather than targeting the whole population, early detection strategies for endometrial cancer could focus on women at high risk of developing endometrial cancer, while excluding most women at low risk. Postmenopausal bleeding (PMB) is a common symptom of endometrial cancer and accounts for approximately two-thirds of all gynecologic visits among perimenopausal and postmenopausal women. 18 Women presenting with PMB undergo additional clinical testing using a combination of transvaginal ultrasonography (TVUS), hysteroscopy, endometrial biopsy, and/or dilation and curettage, and workup varies widely among different settings. [18] [19] [20] However, PMB is often associated with benign conditions such as endometrial polyps or may result from unscheduled bleeding in women using hormone therapy (HT). 18, 21 The risk of endometrial cancer in women with PMB varies widely in individual studies from 3% to 25%. [22] [23] [24] [25] [26] [27] Accurate estimates of the prevalence of PMB in endometrial cancers (equal to the sensitivity of PMB for detecting endometrial cancer) and the risk of endometrial cancer in women with PMB (equal to the positive predictive value [PPV] of PMB for detecting endometrial cancer) are needed to evaluate whether targeting women with PMB for early detection is a useful strategy, particularly because endometrial cancer rates are increasing in the population. A high sensitivity of PMB would ensure that most cases of endometrial cancer are being captured by targeting this population. A high PPV of PMB, which translates into a low number needed to diagnose (1/PPV) to find 1 case of endometrial cancer, would support diagnostic workup of women with PMB, whereas a low PPV would signify the need for additional triage to improve performance of early detection. Furthermore, these estimates would provide the foundation for evaluating clinical and epidemiologic risk prediction models 28 and are necessary for evaluating novel molecular markers that are currently under development against established methods.
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We conducted a systematic review and meta-analysis to evaluate the prevalence of PMB in women with endometrial cancer and the risk of endometrial cancer among women with PMB. Our estimates could inform the evaluation of clinical scenarios to assess the utility of early detection strategies for endometrial cancer.
Methods

Search Strategy and Selection Criteria
We conducted this systematic review and meta-analysis following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (eFigure 1 in the Supplement). 34 We included original studies with primary data reporting the prevalence of PMB in women with endometrial cancer and the risk of endometrial cancer among women with PMB. We searched English-language, peer-reviewed studies published before February 1, 2017, in the MEDLINE database via PubMed and Embase using search terms described in eMethods in the Supplement. We also reviewed the reference lists of articles identified in the primary search for additional relevant studies. Titles and abstracts were independently screened for inclusion by 3 investigators (M.A.C., A.D.M., and B.J.L.). Full-text versions of eligible articles were reviewed by 2 investigators (M.A.C. and B.J.L.) to determine eligibility; any questions regarding the inclusion of studies were resolved by the senior author (N.W.). We evaluated data on patient selection criteria, sample size, and exposure and outcome ascertainment to determine study quality and generalizability; we excluded studies that included special populations (eg, defined by comorbid conditions or specific histologic findings), lacked detailed inclusion criteria, and/or included 25 or fewer women.
by the World Health Organization for those with 2 or more countries represented. 1 Study designs were classified as retrospective or prospective if follow-up time was specified or as cross-sectional (or case series). We assessed study quality using items from the Newcastle-Ottawa Quality Assessment Scale 35 and the Quality Assessment of Diagnostic Accuracy Studies tool 36 (eMethods in the Supplement). We provide the detailed algorithms of how PMB was evaluated for each study in eTable 1 in the Supplement. Studies were classified as having potential verification bias if receipt or interpretation of the diagnostic test (eg, endometrial biopsy) depended on the results of a prior clinical test (eg, TVUS) (eMethods in the Supplement).
Data Synthesis and Analysis
We estimated pooled prevalence and 95% CIs using multilevel logistic-normal random-effects models to account for interstudy heterogeneity. Between-study variance was quantified using the τ 2 statistic. 37, 38 We visualized variation in study-specific estimates using forest plots and performed subgroup analyses (described in eMethods in the Supplement) to evaluate the influence of (1) study exclusion criteria for HT use (analysis of risk of endometrial cancer in women with PMB only); (2) geographical region; and (3) study enrollment period, using the last year of study enrollment or publication date as a proxy, grouped as before 1990, 1990 to 1999, 2000 to 2009, and 2010 to 2017 . We use the P value for heterogeneity to compare subgroup estimates, with significance at P < .05. The influence of continuous study-level (mean) characteristics, including age, years since menopause, and percentage using HT, was explored using multilevel logistic randomeffects models for studies with available data. We conducted sensitivity analyses to assess the influence of clinical setting (tertiary center vs other), study design, and the potential for publication bias using Egger regression analyses. 29 For the analysis of the prevalence of PMB in women with endometrial cancer, we excluded 2 studies 39,40 that selected cases based on stage at diagnosis; however, these studies were included in the stage-specific analysis. For the analysis of the risk of endometrial cancer among women with PMB, we conducted a secondary analysis in a subset of 10 studies [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] that excluded women with measurements below a minimum endometrial thickness determined by TVUS (range, 4-5 mm) and a separate subset of 7 studies 51-57 that evaluated the risk of endometrial cancer in women with polyps.
As an ancillary analysis, we simulated the performance of 2 approaches for early detection of endometrial cancer in a hypothetical population of 10 000 women with PMB to demonstrate how our results can be used to evaluate current testing strategies and the potential clinical value of early-stage biomarkers for endometrial cancer detection: TVUS (cutoff of ≤3 mm), which is a well-established, clinically validated test, 18 and an experimental methylation marker assay 31, 32 (eMethods in the Supplement).
All analyses were performed in Stata, version 13 (StataCorp). For pooling of proportions, we used the program metaprop_one.
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Results
We identified 2398 studies, of which 129 were eligible for our analysis, [22] [23] [24] [25] [26] [27] with 40 790 unique patients, including 1 study 58 that was eligible for both analyses (overlap of 45 women with endometrial cancers and 45 women with PMB) (eFigure 1intheSupplement). Studies were published from January 1, 1977, through January 1, 2017, and most were cross-sectional and conducted in Northern (26 [20.2%] ) and Southern Europe (24 [18.6%] ). Among eligible studies, 21 39, 40, [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [74] [75] [76] [77] were included for analysis of the prevalence of PMB in women with endometrial cancer (3792 cases of endometrial cancer, of which 3257 were in women with PMB, including the 2 studies restricted to stages III-IV cancers 39, 40 ) and 92 [22] [23] [24] [25] [26] [27] 58, were included for analysis of the risk of endometrial cancer in women with PMB (31 220 women with PMB and 2611 cases of endometrial cancer).
Prevalence of PMB in Women With Endometrial Cancer
Study-specific and pooled estimates of the prevalence of PMB in women with endometrial cancer are shown in Figure 1 . The prevalence of PMB was 90% (95% CI, 84%-94%), with substantial between-study variance (τ 2 = 1.14). Removal of a potential outlier 74 resulted in a similar pooled prevalence of 91% (95% CI, 87%-93%), but strong reduction of variance between studies (τ 2 = 0.47); therefore we excluded the outlier study from the remaining analyses. Among 5 studies 66, 70, 72, 75, 76 with information on stage I tumors, the proportion of PMB was 94% (95% CI, 72%-99%; τ 2 = 4.03). Among the 7 studies 39, 40, 66, 70, 72, 75, 76 with information on stages II to IV tumors, the proportion of PMB was 84% (95% CI, 71%-92%; τ 2 = 0.93). We found no significant difference in prevalence of PMB by stage (P = .20 for heterogeneity)(eFigure2intheSupplement).
In an analysis stratified by geographic region, the prevalence of PMB ranged from 94% (95% CI, 84%-97%) in North America to 90% in Western Asia (95% CI, 85%-94%) and Eastern Asia (95% CI, 83%-94%) (P = .55 for heterogeneity) (eFigure 3 in the Supplement). The pooled prevalence of PMB among women with endometrial cancer varied significantly by study enrollment period (P < .001 for heterogeneity). The prevalence of PMB in women with endometrial cancer was higher in studies that enrolled women before 1990 (94%; 95% CI, 92%-95%) and in 1990 to 1999 (96%; 95% CI, 87%-99%) compared with studies that enrolled women in 2000 to 2009 (85%; 95% CI, 78%-90%) and in 2010 to 2017 (86%; 95% CI, 82%-90%) (eFigure 4 in the Supplement).
In a sensitivity analysis restricted to 11 studies 59,62,64,66-68, 70-72,75,76 (67%) that ascertained PMB through retrospective medical record review, the pooled prevalence of PMB was 91% (95% CI, 85%-94%), similar to our overall findings. The prevalence of PMB did not vary significantly by clinical setting. No evidence of publication bias was found among studies reporting the prevalence of PMB in women with endometrial cancer (Egger regression intercept, 0.15; P = .90).
Risk of Endometrial Cancer in Women With PMB
Study-specific and pooled estimates of the risk of endometrial cancer in women with PMB are shown in Figures 2 and 3 . In 92 studies, [22] [23] [24] [25] [26] [27] 58, the risk of endometrial cancer ranged from 0% to 48%, yielding an overall pooled estimate of 9% (95% CI, 8%-11%), with moderate variability observed between studies (τ 2 = 0.56).
The pooled risk of endometrial cancer was significantly higher among the 41 studies 22, 24, 58, 82, 89, [92] [93] [94] 98, 99, [101] [102] [103] [104] [105] [106] 112, 115, 116, 118, 120, 121, 127, 133, [136] [137] [138] 140, 141, [143] [144] [145] [146] [147] 149, 150, 152, 158, [160] [161] [162] that excluded women using HT (12%; 95% CI, 9%-15%; τ 2 =0 . 64 ) ( Figure 4 ) compared with the 51 studies that included women using HT 21, 23, [25] [26] [27] [78] [79] [80] [81] [83] [84] [85] [86] [87] [88] 90, 91, [95] [96] [97] 100, [107] [108] [109] [110] [111] 113, 114, 117, 119, [122] [123] [124] [125] [126] [128] [129] [130] [131] 134, 135, 139, 142, 148, 151, [153] [154] [155] [156] [157] 159 (7%; 95% CI, 6%-9%; τ 2 = 0.38; P < .001 for heterogeneity) (eFigure 8 in the Supplement). The risk of endometrial cancer in women with PMB was lowest in North America (5%; 95% CI, 3%-11%; τ 2 = 0.78) and Northern Europe (7%; 95% CI, 5%-8%; τ 2 = 0.24) and highest in Western Europe (13%; 95% CI, 9%-19%; τ 2 = 0.61) (P = .09 for heterogeneity) (eFigure 5 in the Supplement). In an analysis restricted to European countries only, the risk of endometrial cancer was significantly higher in Western Europe compared with Northern and Southern Europe (P = .03 for heterogeneity). After stratifying by exclusion of women who used HT, significant regional differences persisted in both strata (P = .02 for heterogeneity in studies that included women using HT; P < .001 for heterogeneity in studies that excluded women using HT). The risk of endometrial cancer was significantly higher in studies with enrollment periods before 1990 (13%; 95% CI, 10%-17%; τ 2 = 0.18) and in 1990 to 1999 (11%; 95% CI, 8%-13%; τ 2 = 0.57) compared with 2000 to 2009 (7%; 95% CI, 5%-9%; τ 2 = 0.47) and 2010 to 2017 (8%; 95% CI, 5%-12%; τ 2 = 0.59) (P < .001
for heterogeneity) (eFigure 6 in the Supplement). The risk of endometrial cancer was not significantly associated with mean age, number of years since menopause, and percentage of women using HT. The risk of endometrial cancer was significantly lower in prospective 22, 26, 27, 58, 88, 105, [122] [123] [124] 135, [138] [139] [140] 150 (6%; τ 2 = 0.34) and retrospective 23, 25, 83, 94, 97, 113, 125, 131, 134, 147, 148, 151, 153, 155, 158, 161 (6%; τ 2 = 0.37) studies compared with cross-sectional studies [78] [79] [80] [81] [82] [84] [85] [86] [87] [90] [91] [92] [93] 95, 96, [98] [99] [100] [101] [102] [103] [104] [106] [107] [108] [109] [110] [111] [112] [114] [115] [116] [117] [118] [119] [120] [121] [126] [127] [128] [129] [130] 132, 133, 136, 137, [141] [142] [143] [144] [145] [146] 149, 152, 154, 156, 157, 159, 160, 162 (11%; τ 2 = 0.49; P < .001 for heterogeneity) and was significantly higher in 6 studies 24, 110, 121, 130, 152, 157 conducted in tertiary centers (23%; 95% CI, 17%-31%; τ 2 = 0.18; P < .001 for heterogeneity), compared with studies conducted in other settings. Evidence of publication bias suggested that small studies may overestimate the risk of endometrial cancer in women with PMB (Egger regression intercept, 0.75; P = .001). In an analysis based on the assessment of study quality, verification bias could be excluded in 71 studies [24] [25] [26] 58, 78, 79, [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [98] [99] [100] [101] [102] [103] [104] [105] [106] 108, [110] [111] [112] [113] [114] [115] [117] [118] [119] [120] [121] [122] 125, 126, 128, [130] [131] [132] [133] [135] [136] [137] [139] [140] [141] [143] [144] [145] [146] [147] 149, 150, 152, 154, [156] [157] [158] 161, 162 and was potentially present in 13 studies 22,27,107,109,123,124,127,129,138,142,148,155,159 (8 were unclear) . The risk of endometrial cancer was significantly lower in studies with potential verification bias (6%; 95% CI, 4%-9%) compared with those with no verification bias (10%; 95% CI, 8%-12%) (eTable 2 and eFigure 7 in the Supplement).
In the 10 studies 41-50 that included women with PMB and a minimum endometrial thickness (n = 2087), the pooled risk of endometrial cancer was 19% (95% CI, 14%-25%; τ 2 =0.28).In7 studies 51-57 restricted to women with PMB and polyps (n = 2801), the pooled risk of endometrial cancer was 3% (95% CI, 3%-4%; τ 2 =0).
To demonstrate how the estimates from this metaanalysis can be used to evaluate strategies for endometrial cancer detection in women with PMB, we evaluated the performance of TVUS, a well-established clinical test for evaluating PMB 18 and an experimental methylation assay for endometrial cancer detection 31, 32 in a hypothetical population of 10 000 women with PMB. We evaluated endometrial cancer risk estimates of 5%, 10%, and 15%, representing the range of risks observed in different geographic regions (Table) . We show the The pooled risk of endometrial cancer in all 92 studies is indicated by the dotted line. ES indicates effect size. magnitude of the increase in PPV of both tests with increasing risk of endometrial cancer in women with PMB, supporting the evaluation of early-detection strategies in various populations.
Discussion
The projected rise in endometrial cancer incidence and mortality underscores the importance of strategies for early detection and prevention. Focusing on women at highest risk of endometrial cancer can greatly improve the performance of a diagnostic test and avoid unnecessary testing and associated harms among women at low risk. Our systematic review and meta-analysis demonstrates that PMB is very sensitive for endometrial cancer detection, occurring in approximately 90% of cases. However, our findings indicate that among women with PMB, only approximately 9% will be diagnosed with endometrial cancer, with estimates varying substantially by HT use, geographic region, and the presence of endometrial polyps. Current practice guidelines recommend workup to rule out endometrial cancer among all women with PMB. Our findings support this recommendation by providing reassurance that targeting this high-risk group of women for early detection and prevention strategies will capture most endometrial cancers. However, the low PPV of PMB emphasizes the need for additional triage tests with high specificity to improve management of PMB and avoid unnecessary biopsies in low-risk women.
The prevalence of PMB in endometrial cancer and the risk of endometrial cancer in women with PMB were higher before 2000 compared with after 2000. When interpreting these results, it is important to distinguish population risk, which has generally increased over time, from the risk in women with PMB. The number of endometrial cancers without PMB and the number of women with PMB with benign conditions may both have increased over time. This increase could be influenced by factors such as changes in HT use, changes in prevalence of obesity, or changes in clinical management thresholds for abnormal bleeding. The risk of endometrial cancer among women with PMB was notably lower in studies that included HT users compared with those that excluded these women. Use of HT may affect this association at multiple levels. Certain combined formulations of estrogen plus progestin therapy are established to have a protective effect on the endometrium. 163 Furthermore, irregular uterine bleeding is a common adverse effect of HT, particularly within the first 6 months of use. 164 The underlying causes of HT-induced bleeding is thought to involve changes in the size of endometrial blood vessels and regulation of vascular growth and integrity.
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Because this type of bleeding is generally not associated with abnormal endometrial histologic findings, most guidelines recommend against clinical workup of women using HT who experience irregular uterine bleeding within the first 6 months. However, little consensus exists about how to best treat these women if bleeding persists, and a considerable number of women with HT-associated bleeding will undergo procedures to rule out endometrial cancer. 165 Our data emphasize the importance of considering a woman's HT status to inform clinical decision making, potentially supporting a less aggressive management approach in HT users. We noted striking geographic differences in endometrial cancer risk among women with PMB, ranging from 13% in Western Europe to 5% in North America and 7% in Northern Europe. At present, consensus regarding the optimal approach for evaluating PMB is lacking. Practice may vary depending on resources, clinical expertise and judgment, and patient preferences. The threshold for evaluating PMB may be lower in North American countries compared with other countries in Europe and elsewhere. In many European countries, guidelines recommend TVUS as the first-line test, with histologic assessment indicated for women with a thickened endometrium based on cutoffs ranging from 3to5mm. 18, 166, 167 In the United States, guidelines recommend TVUS or endometrial biopsy as the first step in evaluating PMB.
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In sensitivity analyses, we observed a lower risk of endometrial cancer in studies with partial disease verification (ie, not all women received a biopsy) compared with studies with complete diagnostic verification, suggesting that disease may have been missed in women with negative findings for the first-line test (eg, TVUS). However, we cannot exclude that in some settings, women only received a first-line test such as TVUS if they had a lower risk of endometrial cancer. In the subset of studies included in our meta-analysis that included women with PMB and a minimum endometrial thickness, the pooled risk of endometrial cancer was 19%, more than double the risk observed in our main analysis. Our findings also suggest substantial variation in the risk of endometrial cancer depending on the underlying cause of PMB. Endometrial polyps are one of the most common causes of PMB. Although polyps have been associated with risk of endometrial cancer in women with PMB, 168 other studies have suggested that this association is more likely attributed to detection bias, resulting from incidental findings during the diagnostic workup of PMB caused by endometrial polyps. 169 Our meta-analysis confirms a lower risk of endometrial cancer among women with PMB and polyps.
Strengths and Limitations
To our knowledge, this systematic review and meta-analysis is the first to evaluate the prevalence of PMB in endometrial cancer and the risk of endometrial cancer in women with PMB, 2 important variables for evaluating the role of PMB in early detection of endometrial cancer. Our findings can support risk-informed decision making in clinical management of women with PMB. As an example, we simulated the performance of TVUS, an established diagnostic tool, and methylation markers, an early-phase biomarker, for early detection of endometrial cancer. We provided estimates of how many women would be referred for endometrial biopsy for combinations of endometrial cancer risk in women with PMB, and we showed how many women would need to undergo endometrial biopsy to identify 1 case.
However, a few study limitations are worth noting. In general, data on study-level variables such as years since menopause and body mass index were inconsistently reported, limiting our ability to evaluate them. In addition, insufficient data were available to explore differences by histologic findings, stage, and grade. Whether cancers with more favorable histologic findings (eg, endometrioid type I tumors) are more likely to present with PMB compared with more aggressive histologic subtypes (eg, serous type II tumors) remains unknown. Our results suggest that approximately 10% of women diagnosed with endometrial cancer do not present with PMB. Given the cross-sectional nature of most studies included in this meta-analysis, additional studies linking clinical records with cancer registry data may be warranted to validate our findings. With respect to the analysis of the risk of endometrial cancer in women with PMB, most studies were crosssectional, and few included prospective follow-up; thus, we were unable to evaluate long-term risk of endometrial cancer in these studies. Finally, our results suggested a lower prevalence of endometrial cancer in retrospective and prospective cohort studies compared with cross-sectional studies. Cross-sectional studies may have been more likely to include women with recurrent bleeding; however, few studies distinguished between incident vs recurrent PMB.
Conclusions
The widespread practice of referring all women with PMB for TVUS and/or endometrial biopsy carries a considerable burden and cost. Given the rise in endometrial cancer incidence and mortality, our findings raise the important question of how to best manage PMB to optimize the benefit of early detection approaches while avoiding unnecessary harms. Interest has increased in the use of biomarkers, such as DNA methylation, to improve early detection of endometrial cancer. 31, 32, 170, 171 To obtain reliable estimates of the clinical performance of molecular assays, diagnostic tests, and management algorithms, we must know the prior risk of endometrial cancer in the population.
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Our study represents an important and timely evaluation of the risk of endometrial cancer in women with PMB and can serve as a reliable reference for the prevalence of PMB in women with endometrial cancer and the risk of endometrial cancer in women with PMB, 2 requisite prior probabilities for prediction of endometrial cancer risk and secondary and tertiary prevention. As new markers are discovered or new clinical management strategies are evaluated, our results can aid in the assessment of their potential clinical value and will help to inform clinical and epidemiologic risk prediction models to support clinical decision making. Author Contributions: Dr Clarke had full access to the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: Long, Bakkum-Gamez, Wentzensen. Acquisition, analysis, or interpretation of data: All authors. Drafting of the manuscript: Clarke, Bakkum-Gamez, Wentzensen.
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Additional Contributions: Barbara Brandys, BASc, Office of Research Services, National Institutes of Health Library, assisted with the literature search. She was not compensated for this work. is no effective endometrial cancer screening strategy for women who are asymptomatic. Fortunately, endometrial cancer is typically diagnosed in an early stage; 67% of women present with stage I or II disease confined to the uterus, at which point there is a 95% 5-year survival. 2 Why are the 5-year survival rates of women with endometrial cancer so much higher than for women with other gynecologic cancers? One possible explanation is that women recognize that vaginal bleeding after menopause is not normal and present for medical evaluation, which offers the opportunity for early diagnosis among women who are symptomatic. The American Cancer Society recommends that, at menopause, clinicians inform women that vaginal bleeding is a symptom of endometrial cancer and urge them to seek medical attention if the symptom develops. 3 However, postmenopausal bleeding affects up to 10% of women and can be caused by nonmalignant etiologies, including endometrial atrophy, polyps, and uterine leiomyoma. Given the prevalence of postmenopausal bleeding and its association with both endometrial cancer and benign conditions, accurately quantifying the risk of cancer among women who are symptomatic is paramount. In this issue of JAMA Internal Medicine, Clarke et al 4 provide a well-executed systematic review and meta-analyses of the prevalence of postmenopausal bleeding among women with endometrial cancer (sensitivity) and the risk of endometrial cancer among women with postmenopausal bleeding (positive predictive value). This study 4 suggests that, among women with endometrial cancer, the prevalence of postmenopausal bleeding is 91%. A challenge with many cancers is that individuals do not have symptoms until they have progressed to late-stage disease, but this is not the case for endometrial cancer. Among women with stage I endometrial cancer, 94% had postmenopausal bleeding. The symptom of postmenopausal bleeding is highly sensitive for endometrial cancer, even in its earliest and most treatable stages, and substantiates recommendations from the American College of Obstetricians and Gynecologists that women with postmenopausal bleeding are promptly evaluated.
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Clarke et al 4 balance their optimism regarding the sensitivity of the symptom of postmenopausal bleeding with concerns about its positive predictive value because only 9% of women with postmenopausal bleeding were diagnosed with endometrial cancer. However, rectal bleeding has a similar positive predictive value for colon cancer (8%) and palpable breast lumps have a similar positive predictive value for breast cancer (10%), and evaluation of these symptoms with additional clinical examinations, imaging, biopsies, minor procedures, or a combination of tests is routinely recommended. 6,7 Strategies with fewer false positives (ie, fewer women without cancer subjected to additional evaluation) could decrease patient and health care system burdens. However, evaluating 100 women with postmenopausal bleeding to diagnose 9 endometrial cancers does not seem excessive considering the number of women who are asymptomatic who would need to be screened (if screening were available) to diagnose a single cancer. Among women ages 60 to 64 years, the overall incidence of cancer of the uterus is 96.6 per 100 000; among women with postmenopausal bleeding the incidence is 93 times higher. Because we adapted these scales to be compatible with the studies included in our meta analysis, we did not use an official scoring system; however, we ranked individual items according to the following color coding scale: i. Green = high quality ii. Orange = fair quality iii. Red = poor quality c. The potential for verification bias was determined by items 7 and 8. If receipt or interpretation of the diagnostic test was dependent on the results of a prior clinical test (e.g., vaginal ultrasound) then studies were classified as having potential verification bias. 5. Statistical analysis a. Aims 1 and 2: Pooled prevalence estimates and 95% confidence intervals were estimated using logistic normal random effects models (metaprop_one in Stata version 13). b. For Aim 1, we focused on studies that did not restrict by cancer stage. However, in a sub analysis, we analyzed the prevalence of PMB, stratified by stage (I and II IV cancers) (Figure 1 ). c. Subgroup meta analyses to evaluate potential sources of heterogeneity:
i. Study exclusion criteria for hormone therapy use (Aim 2). Because hormone therapy is known to cause bleeding in postmenopausal women we wanted to evaluate the influence of hormone therapy use on the risk of endometrial cancer in women with PMB using study level summary data. ii. Geographical regions, defined by the World Health Organization for those in which more than one country was represented(22). We evaluated the influence of geographic regions because the risk of endometrial cancer and the clinical management of postmenopausal bleeding varies in different settings. iii. Study enrollment period If study enrollment dates were unavailable, publication date was used as a proxy. Years were grouped as <1990, 1990 1999, 2000 2009, and 2010 2017 . Given the temporal trends in endometrial cancer incidence and changes in clinical management over time, we wanted to evaluate the influence of time period, approximated by using study enrollment dates. d. Multilevel logistic random effects models to evaluate the influence of continuous study level (average) characteristics: i. Age ii. Number of years since menopause iii. Percent of women using hormone therapy e. Sensitivity analyses: 
